Skip to content

Study · Non-randomized trial · n = 50 · 1994

1 result

Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens.

Devroey P, Mannaerts B, Smitz J, Coelingh Bennink H, Van Steirteghem A

Human reproduction (Oxford, England)1 Jun 1994Cited by 46 (Europe PMC)

PMID7962377 (opens in a new tab)DOI10.1093/oxfordjournals.humrep.a138634 (opens in a new tab)PepBankPUB-07962377
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialActivity measurement

    In women undergoing IVF, endogenous LH was most profoundly suppressed in triptorelin protocols on the day of HCG administration.

    In plain wordsIn women undergoing IVF, triptorelin protocols suppressed natural luteinizing hormone more than the other evaluated protocols.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseEndogenous LH suppression
    Study

    n = 50

    Comparator
    Other evaluated recFSH protocols
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg single dose (group IV) or 200 micrograms daily (group V) · intramuscular (group IV) or subcutaneous (group V)As given in this study (human).

    Source sentences

    Summary
    On the day of human chorionic gonadotrophin (HCG) administration, endogenous LH was most profoundly suppressed in subjects treated with triptorelin.
    2 context sentences
    Summary · context
    In total, 50 couples participated in a pilot study evaluating the efficacy of various regimens of gonadotrophin-releasing hormone agonist (GnRHa) in association with recombinant human follicle-stimulating hormone (recFSH) in women undergoing in-vitro fertilization (IVF) and embryo transfer.
    Summary · context
    or using triptorelin in a long protocol, giving a single dose of 3.75 mg i.m. (group IV) or daily s.c. injections of 200 micrograms (group V).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.